公开(公告)号：US11667976B2

公开(公告)日：2023-06-06

申请号：US17097510

申请日：2020-11-13

Applicant: The Johns Hopkins University

Inventor： Bert Vogelstein ,  Kenneth W. Kinzler ,  Luis Diaz ,  Nickolas Papadopoulos ,  George J. Netto ,  Ralph Hruban ,  Isaac A. Kinde

IPC: C12Q1/6886

CPC classification number: C12Q1/6886 ,  C12Q2600/156

Abstract: TERT promoter mutations occur in both papillary and flat lesion bladder cancers, are the most frequent genetic alterations identified to date in noninvasive precursor lesions of the bladder, are detectable in urine, and appear to be strongly associated with bladder cancer recurrence. The TERT promoter mutations are useful urinary biomarker for both the early detection and monitoring of bladder neoplasia.

公开(公告)号：US11649287B2

公开(公告)日：2023-05-16

申请号：US17465096

申请日：2021-09-02

Applicant: The Johns Hopkins University

Inventor： Luis Diaz ,  Bert Vogelstein ,  Kenneth W. Kinzler ,  Nickolas Papadopoulos ,  Dung Le ,  Drew M. Pardoll ,  Suzanne L. Topalian

IPC: G01N31/00 ,  G01N33/53 ,  C07K16/28 ,  C12Q1/6886 ,  C07K16/30 ,  C07K16/40 ,  A61K39/00

CPC classification number: C07K16/2803 ,  C07K16/2818 ,  C07K16/2827 ,  C07K16/30 ,  C07K16/40 ,  C12Q1/6886 ,  C12Y113/11052 ,  A61K2039/505 ,  A61K2039/55 ,  C07K2317/00 ,  C07K2317/24 ,  C07K2317/76 ,  C12Q2600/106 ,  C12Q2600/156

Abstract: Blockade of immune checkpoints such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1) shows promise in patients with cancer. Inhibitory antibodies directed at these receptors have been shown to break immune tolerance and promote anti-tumor immunity. These agents work particularly well in patients with a certain category of tumor. Such tumors may be particularly susceptible to treatment because of the multitude of neoantigens which they produce.

公开(公告)号：US11634491B2

公开(公告)日：2023-04-25

申请号：US17739278

申请日：2022-05-09

Applicant: The Johns Hopkins University

Inventor： Luis Diaz ,  Bert Vogelstein ,  Kenneth W. Kinzler ,  Nickolas Papadopoulos ,  Dung Le ,  Drew M. Pardoll ,  Suzanne L. Topalian

IPC: G01N31/00 ,  G01N33/53 ,  C07K16/28 ,  C12Q1/6886 ,  C07K16/30 ,  C07K16/40 ,  A61K39/00

Abstract: Blockade of immune checkpoints such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1) shows promise in patients with cancer. Inhibitory antibodies directed at these receptors have been shown to break immune tolerance and promote anti-tumor immunity. These agents work particularly well in patients with a certain category of tumor. Such tumors may be particularly susceptible to treatment because of the multitude of neoantigens which they produce.

公开(公告)号：US11439669B2

公开(公告)日：2022-09-13

申请号：US16836003

申请日：2020-03-31

Applicant: BIOMED VALLEY DISCOVERIES, INC. ,  THE JOHNS HOPKINS UNIVERSITY

Inventor： Saurabh Saha ,  Shibin Zhou ,  Bert Vogelstein ,  Kenneth W. Kinzler

IPC: A61K35/74 ,  A61K35/742 ,  A61K31/65 ,  A61K45/06 ,  A61N5/10 ,  A61K35/00

Abstract: The present invention provides, inter alia, methods for treating or ameliorating an effect of a solid tumor present in a human. These methods include administering intratumorally to the human a unit dose of C. novyi, preferably C. novyi NT, colony forming units (CFUs), which contains about 1×103-1×107 CFUs suspended in a pharmaceutically acceptable carrier or solution. Methods for debulking a solid tumor present in a human, methods for ablating a solid tumor present in a human, a method for microscopically precise excision of tumor cells in a human, methods for treating or ameliorating an effect of a solid tumor that has metastasized to one or more sites in a human, unit doses of C. novyi, preferably C. novyi NT, CFUs, and kits for treating or ameliorating an effect of a solid tumor present in a human are also provided.

公开(公告)号：US11306364B2

公开(公告)日：2022-04-19

申请号：US16928164

申请日：2020-07-14

Applicant: Duke University ,  The Johns Hopkins University

Inventor： Hai Yan ,  Bert Vogelstein ,  Nickolas Papadopoulos ,  Kenneth W. Kinzler ,  Yuchen Jiao ,  Chetan Bettegowda ,  Darell D. Bigner ,  Zachary J. Reitman ,  Patrick J. Killela

IPC: C12Q1/6886 ,  C07H21/04

Abstract: We surveyed 1,230 tumors of 60 different types and found that tumors could be divided into types with low (

公开(公告)号：US11286531B2

公开(公告)日：2022-03-29

申请号：US15749887

申请日：2016-08-11

Applicant: The Johns Hopkins University

Inventor： Yuxuan Wang ,  Bert Vogelstein ,  Kenneth W. Kinzler ,  Luis Diaz ,  Nickolas Papadopoulos ,  Karin Sundfeldt ,  Bjorg Kristjansdottir

IPC: C12Q1/6886

Abstract: A diagnostic test for ovarian cysts is based on the detection of mutations characteristic of the most common neoplasms giving rise to these lesions. With this test, tumor-specific mutations were detected in the cyst fluids of 19 of 24 (79%) borderline tumors and 28 of 31 (90%) malignant ovarian cancers. In contrast, we detected no mutations in the cyst fluids from 10 non-neoplastic cysts and 12 benign tumors. When categorized by the need for exploratory surgery (i.e., presence of a borderline tumor or malignant cancer), the sensitivity of this test was 85% and the specificity was 100%. These tests could inform the diagnosis of ovarian cysts and improve the clinical management of the large number of women with these lesions.

公开(公告)号：US11241402B2

公开(公告)日：2022-02-08

申请号：US16931913

申请日：2020-07-17

Applicant: The Johns Hopkins University

Inventor： Shanmugasundaram Ganapathy-Kanniappan ,  Surojit Sur ,  Bert Vogelstein ,  Kenneth W. Kinzler ,  Jean-Francois Geschwind

IPC: A61K31/19 ,  A61P1/16

Abstract: Methods for treating or preventing liver fibrosis in a subject by administering to the subject a therapeutically effective amount of 3-bromopyruvate (3-BrPA) are provided. In addition, methods for promoting the reversal of an activated hepatic stellate cell (HSC) to an inactivated HSC by contacting the activated HSC with at least one 3-bromopyruvate (3-BrPA) molecule are also provided.

公开(公告)号：US20210395365A1

公开(公告)日：2021-12-23

申请号：US17465101

申请日：2021-09-02

Applicant: The Johns Hopkins University

Inventor： Luis Diaz ,  Bert Vogelstein ,  Kenneth W. Kinzler ,  Nickolas Papadopoulos ,  Dung Le ,  Drew M. Pardoll ,  Suzanne L. Topalian

IPC: C07K16/28 ,  C12Q1/6886 ,  C07K16/30 ,  C07K16/40

Abstract: Blockade of immune checkpoints such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1) shows promise in patients with cancer. Inhibitory antibodies directed at these receptors have been shown to break immune tolerance and promote anti-tumor immunity. These agents work particularly well in patients with a certain category of tumor. Such tumors may be particularly susceptible to treatment because of the multitude of neoantigens which they produce.

公开(公告)号：US20210155693A1

公开(公告)日：2021-05-27

申请号：US17131328

申请日：2020-12-22

Applicant: The Johns Hopkins University

Inventor： Luis Diaz ,  Bert Vogelstein ,  Kenneth W. Kinzler ,  Nickolas Papadopoulos ,  Dung Le ,  Drew M. Pardoll ,  Suzanne L. Topalian

IPC: C07K16/28 ,  C12Q1/6886 ,  C07K16/30 ,  C07K16/40

Abstract: Blockade of immune checkpoints such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1) shows promise in patients with cancer. Inhibitory antibodies directed at these receptors have been shown to break immune tolerance and promote anti-tumor immunity. These agents work particularly well in patients with a certain category of tumor. Such tumors may be particularly susceptible to treatment because of the multitude of neoantigens which they produce.

公开(公告)号：US20210100882A1

公开(公告)日：2021-04-08

申请号：US17077661

申请日：2020-10-22

Applicant: The Johns Hopkins University

Inventor： Erika Darrah ,  Ami A. Shah ,  Livia A. Casciola-Rosen ,  Antony Rosen ,  Christine Joseph ,  Bert Vogelstein ,  Kenneth W. Kinzler ,  Nickolas Papadopoulos

IPC: A61K39/00

Abstract: Autoimmune diseases are thought to be initiated by exposures to foreign antigens that cross-react with endogenous molecules. Analyses of peripheral blood lymphocytes and serum suggested that mutations in autoimmune antigen targets sparked cellular immunity and cross-reactive humoral immune responses. Acquired immunity to autoimmune antigens can help control naturally occurring cancers.